May 21, 2020
Insomnia Data 2020: US Leads in Global Insomnia Clinical Trials, Germany Leads Major European Markets and Japan Has Top Spot in Asia
Dec 27, 2019
Pivotal Phase 3 Study of DAYVIGO(TM) (lemborexant) for the Treatment of Insomnia Disorder Published in JAMA Network Open
Dec 23, 2019
U.S. FDA Approves Eisai's DAYVIGO(TM) (lemborexant) for the Treatment of Insomnia in Adult Patients
Dec 10, 2019
Eisai Presents New Analyses of Potential Blood-Based Alzheimer's Diagnostic Test and Lemborexant as Potential Sleep-Wake Disorder Therapy
Dec 02, 2019
Eisai and Biogen's Joint Investigational Asset BAN2401 Data to be Presented at Clinical Trials on Alzheimer's Disease Conference
Sep 27, 2019
Three New Analyses of Data Expand Understanding of the Potential Role for Investigational Agent Lemborexant in Insomnia and Irregular Sleep-Wake Rhythm Disorder
Sep 19, 2019
Eisai to Present New 12-month Safety & Effectiveness Data from Phase 3 Lemborexant SUNRISE 2 Study and New Patient and Cohabitant Insights about Insomnia and Toll on Next-Day Functioning at World Sleep Congress
Jul 11, 2019
New Data in 2 Oral and 13 Poster Presentations about Eisai's Latest Dementia Pipeline, Including BAN2401, Elenbecestat and Lemborexant, to be Presented at Alzheimer's Association International Conference
Jun 11, 2019
Extensive Analyses of Phase 3 Data for Investigational Lemborexant Assess Efficacy and Safety Profile for the Potential Treatment of Insomnia in Adults
May 28, 2019
Eisai to Present Eight Lemborexant Posters at SLEEP 2019 Meeting, Including New Pooled Analyses From Phase 3 Studies and New Phase 1 Data
Apr 30, 2019
Eisai and Purdue Pharma Announce Buy Out of Purdue's Rights in Worldwide Collaboration to Develop and Commercialize Lemborexant
Mar 11, 2019
Eisai and Imbrium Therapeutics Announce U.S. FDA Filing Acceptance of New Drug Application for Lemborexant for the Treatment of Insomnia
Jan 15, 2019
New Drug Application for Insomnia Disorder Treatment Lemborexant Submitted in the United States
Oct 17, 2018
Eisai and Purdue Pharma Announce Positive Topline Results of SUNRISE 2, the Second Phase 3 Pivotal Study of Lemborexant
Jul 02, 2018
Eisai and Purdue Pharma Announce Oral Presentation of Latest Clinical and Non-Clinical Data on Lemborexant at 43rd Annual Meeting of the Japanese Society of Sleep Research
Jun 05, 2018
Positive New Data on Investigational Lemborexant Presented at 32nd Annual SLEEP Meeting
Mar 07, 2018
Eisai and Purdue Pharma Announce Positive Topline Results From Key Clinical Studies of Lemborexant Including First-Ever Phase 3 Head-to-Head Superiority Comparison Versus Zolpidem ER in Patients With Sleep Disorder
Nov 24, 2017
Global Insomnia Therapeutics Market, 2025 - Market is Expected to Reach USD 3.45 Billion
Nov 01, 2017
Insomnia Therapeutics Market Size Worth $3.45 Billion by 2025: Grand View Research, Inc.
Oct 30, 2017
New Data Highlight Innovative Ways to Assess Patients with Early Alzheimer's Disease and Later Stage Alzheimer's Disease Dementia